Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monopar Therapeutics

37.11
-0.9050-2.38%
Post-market: 37.110.00000.00%16:27 EDT
Volume:19.86K
Turnover:765.97K
Market Cap:226.94M
PE:-10.61
High:39.43
Open:39.27
Low:37.10
Close:38.02
Loading ...

Monopar Therapeutics initiated with a Buy at Lucid Capital

TIPRANKS
·
05 Jun

Monopar Therapeutics to Join Russell Indexes

MT Newswires Live
·
03 Jun

Piper Sandler Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
19 May

Monopar Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Monopar Therapeutics Q1 EPS $(0.38) Beats $(0.68) Estimate

Benzinga
·
13 May

Monopar Therapeutics Q1 2025 Results: Net Loss Increases to $2.6M, EPS at $0.38

Reuters
·
13 May

Press Release: Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Dow Jones
·
13 May

Monopar Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview

Reuters
·
07 May

Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025

Insider Monkey
·
30 Apr

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

GlobeNewswire
·
29 Apr

Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock!

TIPRANKS
·
05 Apr

Monopar Therapeutics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
02 Apr

JonesTrading downgrades Monopar Therapeutics Inc (MNPR) to a Hold

TIPRANKS
·
02 Apr

Monopar Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

Monopar Therapeutics Q4 EPS $(2.23) Down From $(0.60) YoY

Benzinga
·
31 Mar

Press Release: Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Dow Jones
·
31 Mar

Monopar Therapeutics Inc - to Submit Nda for Alxn1840 in Early 2026

THOMSON REUTERS
·
31 Mar

Monopar Therapeutics Inc - Q4 Net Loss of $2.23 per Share

THOMSON REUTERS
·
31 Mar

Monopar Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview

Reuters
·
24 Mar

Monopar Therapeutics Coverage Assumed by Piper Sandler at Overweight

Dow Jones
·
19 Mar